IER3 in pancreatic carcinogenesis

IER3 in pancreatic carcinogenesis

Pancreatic ductal adenocarcinoma (PDAC) has the highest mortality rate of all cancers and the lowest overall survival rate of less than 5% at 5 years. The incidence of PDAC almost equals its mortality rate and is increasing every year, with more than 10,000 predicted new cases in France, 38,000 in the United States and 65,000 in Europe [1]. PDAC is characterized by a stepwise progression of duc...

Possible Involvement of Pancreatic Fatty Infiltration in Pancreatic Carcinogenesis

Pancreatic cancer is difficult to diagnose in its early stage and is one of the most lethal human cancers. Thus, it is important to clarify its major risk factors, predictive factors and etiology. Here, we focus on fatty infiltration of the pancreas and suggest that it could be a risk factor for pancreatic cancer. Fatty infiltration of the pancreas is observed as ectopic adipocytes infiltrating...

Genetic and Epigenetic Alterations in Pancreatic Carcinogenesis

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Despite significant progresses in the last decades, the origin of this cancer remains unclear and no efficient therapy exists. PDAC does not arise de novo: three remarkable different types of pancreatic lesions can evolve towards pancreatic cancer. These precursor lesions include: Pancreatic intraepithelial neo...

IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation.

Activating mutations in the KRAS oncogene are prevalent in pancreatic ductal adenocarcinoma (PDAC). We previously demonstrated that pancreatic intraepithelial neoplasia (PanIN) formation, which precedes malignant transformation, associates with the expression of immediate early response 3 (Ier3) as part of a prooncogenic transcriptional pathway. Here, we evaluated the role of IER3 in PanIN form...

Introduction: national cancer institute pancreatic carcinogenesis program.